...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Impact of Co-morbidities on Outcome of COVID-19 Patients: An Observational Study among Patients Admitted to Intensive Care Uni
【24h】

Impact of Co-morbidities on Outcome of COVID-19 Patients: An Observational Study among Patients Admitted to Intensive Care Uni

机译：共产性对Covid-19患者结果的影响：患者入院密集护理的患者的观察研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Coronavirus Disease-2019 (COVID-19) has been a major cause of apprehension, morbidity, and mortality in 2020. It had been postulated that associated co-morbid conditions in COVID-19 patients increase the severity of COVID-19 which leads to six times more chances of hospitalisation than patients without co-morbid condition. Mortality is also 12 times higher in such patients.Aim: To find out the association between co-morbidities and mortalities due to COVID-19 pneumonia.Materials and Methods: A prospective, observational study was conducted in a tertiary teaching institute of North India which was designated Level 3 (L-3) facility for treatment of COVID19 patients. All 109 COVID-19 patients confirmed by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), admitted in Intensive Care Unit (ICU) from 1st July 2020 to 30th November 2020 formed the sample of the study. Data was taken regarding past history, clinical histories and examinations and ICU care and treatments. Based on their final outcome at the end of ICU care, patients were divided into two groups-group 1 (Non-survivor or Expired) and group 2 (Survived) and intergroup differences were studied.Results: COVID-19 infection was about three times more common in males. Severe category of COVID-19 patients had higher mortality (59.2% of severe category expired during hospital course, 1.7% patients expired in moderate category group). Most common comorbidities were hypertension (n=51, 46.8%) and diabetes (n=48, 44%). Multivariate analysis showed that co-morbidities in the form of chronic liver disease (OR -0.127 (0.024-0.681, p-value 0.016)) and post tubercular sequel (OR 0.036 (0.003-0.442, p-value 0.009)) were less likely to occur in COVID-19 patients who survived, thus making these co-morbidities significant contributor to the adverse outcomes in COVID-19 patients. More number of co-morbidities in a patient were associated with higher chance of mortality and this trend was significant statistically (p-value <0.001).Conclusion: Patients with multiple co-morbidities, chronic liver disease and post tubercular sequel were associated with higher mortality in COVID-19 patients.
机译：冠状病毒病 - 2019年（Covid-19）是2020年的主要原因，发病率和死亡率的主要原因。它已经假定了Covid-19患者的相关持续病态条件增加了Covid-19的严重程度，导致六个由于没有共同病态的患者，住院时间的时间更多。此类患者的死亡率也增加了12倍。被指定为3级（L-3）设施，用于治疗Covid19患者。所有109个Covid-19逆转录酶 - 聚合酶链反应（RT-PCR）证实的患者，在2020年7月1日至2020年7月1日至11月30日的重症监护股（ICU）中被录取为11月30日形成了该研究的样本。数据是关于过去的历史，临床历史和考试和ICU护理和治疗方法。基于ICU护理结束时的最终结果，患者分为两组 - 第1组（非幸存者或过期），第2组（存活）和血液组差异。结果：Covid-19感染约为三次更常见的男性。严重的Covid-19患者的死亡率较高（医院课程的严重类别的59.2％，1.7％的患者在中等类别组中到期。大多数常见的合并症是高血压（n = 51,46.8％）和糖尿病（n = 48,44％）。多变量分析表明，慢性肝病形式（或-0.127（0.024-0.681，p值0.016））和后结核续集（或0.036（0.003-0.442，p值0.009））的共生体不太可能在Covid-19幸存下患者发生，从而使这些共同的患者与Covid-19患者的不良结果有重大贡献。患者的更多数量的患者与较高的死亡率有关，这种趋势是显着的统计学（p值<0.001）。结论：具有多种辅病症，慢性肝病和后结核续期的患者与更高相关Covid-19患者的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号